Matthias Pfisterer
Limited role for fibroblast growth factor 23 in assessing prognosis in heart failure patients: data from the TIME-CHF trial
Stöhr R, Sanders-van Wijk S, Pfisterer M, Jeker U, Schuh A, Leibundgut G, Maeder M, Heine G, Brandenburg V, Brunner-La Rocca H. Limited role for fibroblast growth factor 23 in assessing prognosis in heart failure patients: data from the TIME-CHF trial. Eur J Heart Fail 2020
Feb 5, 2020Limited role for fibroblast growth factor 23 in assessing prognosis in heart failure patients: data from the TIME-CHF trial
Feb 5, 2020Eur J Heart Fail 2020
Stöhr Robert, Sanders-van Wijk Sandra, Pfisterer Matthias, Jeker Urs, Schuh Alexander, Leibundgut Gregor, Maeder Micha, Heine Gunnar H, Brandenburg Vincent M, Brunner-La Rocca Hans-Peter
Prognostic Significance of Longitudinal Clinical Congestion Pattern in Chronic Heart Failure: Insights From TIME-CHF Trial
Simonavičius J, van Empel V, Knackstedt C, Puronaitė R, Čelutkienė J, Pfisterer M, Kaufmann B, Pfister O, Maeder M, Rickenbacher P, Sanders van-Wijk S, Brunner-La Rocca H. Prognostic Significance of Longitudinal Clinical Congestion Pattern in Chronic Heart Failure: Insights From TIME-CHF Trial. Am J Med 2019; 132:e679-e692.
Apr 30, 2019Prognostic Significance of Longitudinal Clinical Congestion Pattern in Chronic Heart Failure: Insights From TIME-CHF Trial
Apr 30, 2019Am J Med 2019; 132:e679-e692
Simonavičius Justas, van Empel Vanessa, Knackstedt Christian, Puronaitė Roma, Čelutkienė Jelena, Pfisterer Matthias, Kaufmann Beat A, Pfister Otmar, Maeder Micha, Rickenbacher Peter, Sanders van-Wijk Sandra, Brunner-La Rocca Hans-Peter
Competing risks of major bleeding and thrombotic events with prasugrel-based dual antiplatelet therapy after stent implantation - An observational analysis from BASKET-PROVE II
Jeger R, Weilenmann D, Rickli H, Hansen K, Rickenbacher P, Conen D, Müller C, Osswald S, Gilgen N, Vuilliomenet A, Pedrazzini G, Pfisterer M, Vogt D, Galatius S, Abildgaard U, Naber C, Alber H, Eberli F, Kurz D, Kaiser C. Competing risks of major bleeding and thrombotic events with prasugrel-based dual antiplatelet therapy after stent implantation - An observational analysis from BASKET-PROVE II. PloS one 2019; 14:e0210821.
Jan 15, 2019Competing risks of major bleeding and thrombotic events with prasugrel-based dual antiplatelet therapy after stent implantation - An observational analysis from BASKET-PROVE II
Jan 15, 2019PloS one 2019; 14:e0210821
Jeger Raban V, Weilenmann Daniel, Rickli Hans, Hansen Kim Wadt, Rickenbacher Peter, Conen David, Müller Christian, Osswald Stefan, Gilgen Nicole, Vuilliomenet André, Pedrazzini Giovanni, Pfisterer Matthias, Vogt Deborah R, Galatius Søren, Abildgaard Ulrik, Naber Christoph, Alber Hannes, Eberli Franz, Kurz David J, Kaiser Christoph
Is the clinical presentation of chronic heart failure different in elderly versus younger patients and those with preserved versus reduced ejection fraction?
Steinmann E, Brunner-La Rocca H, Maeder M, Kaufmann B, Pfisterer M, Rickenbacher P. Is the clinical presentation of chronic heart failure different in elderly versus younger patients and those with preserved versus reduced ejection fraction?. Eur J Intern Med 2018
Jun 13, 2018Is the clinical presentation of chronic heart failure different in elderly versus younger patients and those with preserved versus reduced ejection fraction?
Jun 13, 2018Eur J Intern Med 2018
Steinmann Eva, Brunner-La Rocca Hans-Peter, Maeder Micha, Kaufmann Beat A, Pfisterer Matthias, Rickenbacher Peter
Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF)
Rickenbacher P, Kaufmann B, Maeder M, Bernheim A, Goetschalckx K, Pfister O, Pfisterer M, Brunner-La Rocca H. Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). Eur J Heart Fail 2017
Mar 15, 2017Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF)
Mar 15, 2017Eur J Heart Fail 2017
Rickenbacher Peter, Kaufmann Beat A, Maeder Micha, Bernheim Alain, Goetschalckx Kaatje, Pfister Otmar, Pfisterer Matthias, Brunner-La Rocca Hans-Peter
Can the optimal type of stent be predicted based on clinical risk factors? A subgroup analysis of the randomized BASKET-PROVE trial
Vassalli G, Pedrazzini G, Pfisterer M, Kaiser C, Moccetti T, Bonetti P, Bertel O, Hornig B, Rickli H, Eberli F, Erne P, Galatius S, De Servi S, Klersy C, BASKET-PROVE Investigators. Can the optimal type of stent be predicted based on clinical risk factors? A subgroup analysis of the randomized BASKET-PROVE trial. Am Heart J 2015; 173:1-7.
Dec 1, 2015Can the optimal type of stent be predicted based on clinical risk factors? A subgroup analysis of the randomized BASKET-PROVE trial
Dec 1, 2015Am Heart J 2015; 173:1-7
Vassalli Giuseppe, Pedrazzini Giovanni, Pfisterer Matthias, Kaiser Christoph, Moccetti Tiziano, Bonetti Piero, Bertel Osmund, Hornig Burkhard, Rickli Hans, Eberli Franz, Erne Paul, Galatius Soeren, De Servi Stefano, Klersy Catherine, BASKET-PROVE Investigators
Differential Prognostic Impact of Resting Heart Rate in Older Compared to Younger Patients with Chronic Heart Failure - Insights from TIME-CHF
Zurek M, Brunner-La Rocca H, Pfisterer M, Jeker U, Handschin R, Abbühl H, Sanders-van Wijk S, Muzzarelli S, Rickli H, Maeder M, TIME-CHF Investigators. Differential Prognostic Impact of Resting Heart Rate in Older Compared to Younger Patients with Chronic Heart Failure - Insights from TIME-CHF. J Card Fail 2015
Jan 7, 2015Differential Prognostic Impact of Resting Heart Rate in Older Compared to Younger Patients with Chronic Heart Failure - Insights from TIME-CHF
Jan 7, 2015J Card Fail 2015
Zurek Marzena, Brunner-La Rocca Hans-Peter, Pfisterer Matthias, Jeker Urs, Handschin Rolf, Abbühl Heidi, Sanders-van Wijk Sandra, Muzzarelli Stefano, Rickli Hans, Maeder Micha, TIME-CHF Investigators
Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main results of the Basel Stent Kosten-Effektivitäts Trial-PROspective Validation Examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome trial
Kaiser C, Vuillomenet A, Steiner M, von Felten S, Vogt D, Wadt Hansen K, Rickenbacher P, Conen D, Müller C, Buser P, Hoffmann A, Pfisterer M, Weilenmann D, Rickli H, Galatius S, Jeger R, Gilgen N, Skov Jensen J, Naber C, Alber H, Wanitschek M, Eberli F, Kurz D, Pedrazzini G, Moccetti T, BASKET-PROVE II study group. Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main results of the Basel Stent Kosten-Effektivitäts Trial-PROspective Validation Examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome trial. Circulation 2014; 131:74-81.
Nov 19, 2014Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main results of the Basel Stent Kosten-Effektivitäts Trial-PROspective Validation Examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome trial
Nov 19, 2014Circulation 2014; 131:74-81
Kaiser Christoph, Vuillomenet André, Steiner Martin, von Felten Stefanie, Vogt Deborah R, Wadt Hansen Kim, Rickenbacher Peter, Conen David, Müller Christian, Buser Peter, Hoffmann Andreas, Pfisterer Matthias, Weilenmann Daniel, Rickli Hans, Galatius Soeren, Jeger Raban, Gilgen Nicole, Skov Jensen Jan, Naber Christoph, Alber Hannes, Wanitschek Maria, Eberli Franz, Kurz David J, Pedrazzini Giovanni, Moccetti Tiziano, BASKET-PROVE II study group
Heart rate at discharge and long-term prognosis following percutaneous coronary intervention in stable and acute coronary syndromes--results from the BASKET PROVE trial
Jensen M, Galatius S, Pfisterer M, Erne P, De Servi S, Bertel O, Fahrni G, Zurek M, Rickli H, Soerensen R, Pedersen S, Jensen J, Iversen A, Wanitschek M, Alber H, Sandsten K, Kaiser C, BASKET-PROVE Investigators. Heart rate at discharge and long-term prognosis following percutaneous coronary intervention in stable and acute coronary syndromes--results from the BASKET PROVE trial. Int J Cardiol 2013; 168:3802-6.
Jul 11, 2013Heart rate at discharge and long-term prognosis following percutaneous coronary intervention in stable and acute coronary syndromes--results from the BASKET PROVE trial
Jul 11, 2013Int J Cardiol 2013; 168:3802-6
Jensen Magnus Thorsten, Galatius Søren, Pfisterer Matthias, Erne Paul, De Servi Stefano, Bertel Osmund, Fahrni Gregor, Zurek Marzena, Rickli Hans, Soerensen Rikke, Pedersen Sune, Jensen Jan Skov, Iversen Allan, Wanitschek Maria, Alber Hannes, Sandsten Karl Erik, Kaiser Christoph, BASKET-PROVE Investigators
N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF)
Maeder M, Brunner-La Rocca H, Pfisterer M, Peter M, Vuilliomenet A, Erne P, Gutmann M, Abbühl H, Rickli H, Rickenbacher P, TIME-CHF Investigators. N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF). Eur J Heart Fail 2013; 15:1148-56.
May 8, 2013N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF)
May 8, 2013Eur J Heart Fail 2013; 15:1148-56
Maeder Micha, Brunner-La Rocca Hans-Peter, Pfisterer Matthias, Peter Martin, Vuilliomenet André, Erne Paul, Gutmann Marc, Abbühl Heidi, Rickli Hans, Rickenbacher Peter, TIME-CHF Investigators
Newest-generation drug-eluting and bare-metal stents combined with prasugrel-based antiplatelet therapy in large coronary arteries: the BAsel Stent Kosten Effektivitäts Trial PROspective Validation Examination part II (BASKET-PROVE II) trial design
Jeger R, Gilgen N, Vuilliomenet A, Jensen J, Rickli H, Pedrazzini G, Naber C, Galatius S, Eberli F, Alber H, Pfisterer M, Kaiser C. Newest-generation drug-eluting and bare-metal stents combined with prasugrel-based antiplatelet therapy in large coronary arteries: the BAsel Stent Kosten Effektivitäts Trial PROspective Validation Examination part II (BASKET-PROVE II) trial design. Am Heart J 2012; 163:136-41.e1.
Feb 1, 2012Newest-generation drug-eluting and bare-metal stents combined with prasugrel-based antiplatelet therapy in large coronary arteries: the BAsel Stent Kosten Effektivitäts Trial PROspective Validation Examination part II (BASKET-PROVE II) trial design
Feb 1, 2012Am Heart J 2012; 163:136-41.e1
Jeger Raban, Gilgen Nicole, Vuilliomenet André, Jensen Jan Skov, Rickli Hans, Pedrazzini Giovanni, Naber Christoph, Galatius Søren, Eberli Franz, Alber Hannes, Pfisterer Matthias, Kaiser Christoph
Drug-eluting versus bare-metal stents in large coronary arteries
Kaiser C, Pfisterer M, Ricard I, Brunner-La Rocca H, De Servi S, Bonetti P, Bertel O, Hornig B, Pedrazzini G, Rickli H, Alber H, Eberli F, Erne P, Galatius S, BASKET?PROVE Study Group. Drug-eluting versus bare-metal stents in large coronary arteries. N Engl J Med 2010; 363:2310-9.
Nov 16, 2010Drug-eluting versus bare-metal stents in large coronary arteries
Nov 16, 2010N Engl J Med 2010; 363:2310-9
Kaiser Christoph, Pfisterer Matthias, Ricard Ingrid, Brunner-La Rocca Hans-Peter, De Servi Stefano, Bonetti Piero, Bertel Osmund, Hornig Burkhard, Pedrazzini Giovanni, Rickli Hans, Alber Hannes, Eberli Franz, Erne Paul, Galatius Soeren, BASKET?PROVE Study Group
Predictors of early readmission or death in elderly patients with heart failure
Muzzarelli S, Brunner-La Rocca H, Pfisterer M, Buser P, Jeker U, Gutmann M, Handschin R, Rickli H, Maeder M, Leibundgut G, TIME-CHF Investigators. Predictors of early readmission or death in elderly patients with heart failure. Am Heart J 2010; 160:308-14.
Aug 1, 2010Predictors of early readmission or death in elderly patients with heart failure
Aug 1, 2010Am Heart J 2010; 160:308-14
Muzzarelli Stefano, Brunner-La Rocca Hans-Peter, Pfisterer Matthias, Buser Peter, Jeker Urs, Gutmann Marc, Handschin Rolf, Rickli Hans, Maeder Micha, Leibundgut Gregor, TIME-CHF Investigators
BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial
Pfisterer M, Brunner-La Rocca H, Schindler R, Hilti P, Schieber M, Osterhues H, Suter T, Yoon S, Beer H, Dubach P, Jeker U, Vuillomenet A, Rickenbacher P, Erne P, Gutmann M, Rickli H, Buser P, TIME-CHF Investigators. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA : the journal of the American Medical Association 2009; 301:383-92.
Jan 28, 2009BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial
Jan 28, 2009JAMA : the journal of the American Medical Association 2009; 301:383-92
Pfisterer Matthias, Brunner-La Rocca Hans-Peter, Schindler Ruth, Hilti Patrick, Schieber Michael M, Osterhues Hans H, Suter Thomas, Yoon Se-Il, Beer Hansjürg, Dubach Paul, Jeker Urs, Vuillomenet André, Rickenbacher Peter, Erne Paul, Gutmann Marc, Rickli Hans, Buser Peter, TIME-CHF Investigators
Drug-eluting or bare-metal stents for large coronary vessel stenting? The BASKET-PROVE (PROspective Validation Examination) trial: study protocol and design
Pfisterer M, Kaiser C, De Servi S, Rickli H, Pedrazzini G, Pachinger O, Kiowski W, Hornig B, Galatius S, Erne P, Eberli F, Brunner-La Rocca H, Bonetti P, Bertel O, BASKET-PROVE Investigators. Drug-eluting or bare-metal stents for large coronary vessel stenting? The BASKET-PROVE (PROspective Validation Examination) trial: study protocol and design. American heart journal 2008; 155:609-14.
Apr 1, 2008Drug-eluting or bare-metal stents for large coronary vessel stenting? The BASKET-PROVE (PROspective Validation Examination) trial: study protocol and design
Apr 1, 2008American heart journal 2008; 155:609-14
Pfisterer Matthias, Kaiser Christoph, De Servi Stefano, Rickli Hans, Pedrazzini Giovanni, Pachinger Otmar, Kiowski Wolfgang, Hornig Burkhard, Galatius Soeren, Erne Paul, Eberli Franz R, Brunner-La Rocca Hans Peter, Bonetti Piero O, Bertel Osmund, BASKET-PROVE Investigators
Right atrial pacing impairs cardiac function during resynchronization therapy: acute effects of DDD pacing compared to VDD pacing
Bernheim A, Pfisterer M, Buser P, Linka A, Kaiser C, Kiencke S, Eckstein J, Brunner-La Rocca H, Schaer B, Burger P, Sticherling C, Ammann P, Osswald S. Right atrial pacing impairs cardiac function during resynchronization therapy: acute effects of DDD pacing compared to VDD pacing. Journal of the American College of Cardiology 2005; 45:1482-7.
May 3, 2005Right atrial pacing impairs cardiac function during resynchronization therapy: acute effects of DDD pacing compared to VDD pacing
May 3, 2005Journal of the American College of Cardiology 2005; 45:1482-7
Bernheim Alain, Pfisterer Matthias, Buser Peter, Linka Andre, Kaiser Christoph, Kiencke Stephanie, Eckstein Jens, Brunner-La Rocca Hans Peter, Schaer Beat, Burger Peter, Sticherling Christian, Ammann Peter, Osswald Stefan
Raised cardiac troponins
Ammann P, Pfisterer M, Fehr T, Rickli H. Raised cardiac troponins. BMJ (Clinical research ed.) 2004; 328:1028-9.
May 1, 2004Raised cardiac troponins
May 1, 2004BMJ (Clinical research ed.) 2004; 328:1028-9
Ammann Peter, Pfisterer Matthias, Fehr Thomas, Rickli Hans
Heart rate variability and cardiac troponin I are incremental and independent predictors of one-year all-cause mortality after major noncardiac surgery in patients at risk of coronary artery disease
Filipovic M, Jeger R, Probst C, Girard T, Pfisterer M, Gürke L, Skarvan K, Seeberger M. Heart rate variability and cardiac troponin I are incremental and independent predictors of one-year all-cause mortality after major noncardiac surgery in patients at risk of coronary artery disease. Journal of the American College of Cardiology 2003; 42:1767-76.
Nov 19, 2003Heart rate variability and cardiac troponin I are incremental and independent predictors of one-year all-cause mortality after major noncardiac surgery in patients at risk of coronary artery disease
Nov 19, 2003Journal of the American College of Cardiology 2003; 42:1767-76
Filipovic Miodrag, Jeger Raban, Probst Cecilia, Girard Thierry, Pfisterer Matthias, Gürke Lorenz, Skarvan Karl, Seeberger Manfred D